On May 15, 2015, Respironics, Inc., a Philips business, provided the following response to ResMed's Update on Phase IV SERVE-HF Study of Adaptive Servo-Ventilation (ASV) Therapy in Central Sleep Apnea ...

Primary results from ResMed Inc.’s RMD CAT-HF trial showcased the significance of adaptive servo-ventilation (ASV) therapy in the treatment of heart failure (HF). Data were presented at the European ...

Royal Philips ($PHG) said it is working with ResMed ($RMD) to analyze study data from mid-May showing that the latter company's Adaptive Servo-Ventilation (ASV ...

Medical device company ResMed Inc. RMD recently sponsored a study which shows potential treatment of obstructive sleep apnea (OSA) in patients with untreated central sleep apnea (CSA). According to ...

SAN DIEGO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) launched today its AirCurve 11 series devices, the company’s newest bilevel devices that use two levels of support, ...

Cardiovascular problems can be associated with sleep apnea, and it's commonly assumed that treatment of sleep apnea could have cardiovascular benefits. But a ResMed ...

Auto-Adjusting Pressure : The ResMed AirCurve 11 VAuto BiPAP machine features an automatic adjustment function that allows the device to change pressure settings based on real-time data. This ...

SAN DIEGO, May 13, 2015 /PRNewswire/ -- ResMed (NYSE: RMD) today announced that SERVE-HF, a multinational, multicenter, randomized controlled Phase III trial did not meet its primary endpoint.

SAN DIEGO, May 13, 2015 /CNW/ -- ResMed (NYSE: RMD) today announced that SERVE-HF, a multinational, multicenter, randomized controlled Phase III trial did not meet its primary endpoint. SERVE-HF was ...